New gout pill enters first human tests
NCT ID NCT07324434
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new oral drug called F-02-2-Na in 69 adults with high uric acid levels, with or without gout. The main goal is to check the drug's safety and how the body processes it at different doses. Participants will receive either the drug or a placebo, and researchers will monitor side effects and drug levels in the blood and urine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- F-02-2-Na tablet
- What this could lead to
- If successful, this could lead to a new oral medication to lower uric acid levels and manage gout.
- What could go wrong
- This is a very early Phase 1 study focused on safety and dosing, not yet testing effectiveness. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERURICEMIA WITH OR WITHOUT GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.